Beyond the skill build Biomolecular Needling System for Medicals

Painless Transdermal Drug Delivery & Self-testing Diagnostic Bio-sensors

マイクロニードルパッチ:DDSと予防医学

生体分解性マイクロニードルパッチを用いた 新規Drug Delivery System開発とバイオセンサーへの応用 :新型コロナ感染症の診断パッチ開発と新規ワクチンパッチの開発を目指して








Director of LIMMS/CNRS-IIS UMI 2820 Institute of Industrial Science, The University of Tokyo Chair of Corporate Sponsored Research Division of Virological Medicine









What is better for your Drug Delivery system?



Hypodermic Injection



Oral Inoculation






Drug Patch/ointment

BNS MEDICALS

マイクロニードル: 痛みのない針



34G:外径(0.18 mm)



- □ 血管や神経を傷つけない針
- □ 痛みや出血を伴わずに生体内にアクセス可能
- □ 真皮層中の細胞間質液の採取への期待


BNS MEDICALS

Microneedle Array


• Microneedles (MNs), MN array

micrometer sized needles made of various biocompatible materials.

- > can create the pathways into epidermis or dermis layers to transport drug molecules.
- > minimally invasive, no medical professionals, convenient in storage as well as logistics




Conventional Micro Needles for Drug Delivery System




Refs: Y.C. Kim, et al., Advanced Drug Delivery Reviews 64 (2012) 1547–1568

BNS MEDICALS

Various Types of Micro Needles for DDS






Hollow Micro needle

BNS MEDICALS

Refs: Y.C. Kim, et al., Advanced Drug Delivery Reviews 64 (2012) 1547-1568


Micro Needles : Dissolving Micro needle (Biodegradable)







Existing conventional Dissoluble Micro Needle Patch for DDS 生体分解性マイクロニードルを用いたドラッグデリバリーシステムの革命と予防医学の実現



100 % transdermal local delivery of high molecule API (Active Pharmaceutical Ingredient)

Commercialization Dissolving Micro needle

EGF (Epidermal Growth Factor,上皮成長因子) and Hyaluronic Acid

+ Argireline (Acetylhexapeptide-3)



Cosmetic

<u>Prof. Stanley Cohen</u> Nobel prize in Physiology & Medicine to discover **EGF** (1986)




MEDICINE

1 Microneedles for Painless Injections and Tests

Fewer trips to medical labs make care more accessible

Experts highlight advances with the potential to revolutionize industry, healthcare and society






BNS MEDICALS

Microneedle Array

• Microneedles (MNs), MN array, Microneedle patch (MNP)

micrometer sized needles made of various biocompatible materials.


- > can create the pathways into epidermis or dermis layers to transport drug molecules.
- > minimally invasive, no medical professionals, convenient in storage as well as logistics



Currently, Dissolving Microneedles


Problems

- Commercialized only in Cosmetic, skin trouble care products
 Still very few in DDS (acne care, influ vaccination, research levels for medical applications)
- Minimally invasive manner still inevitable pain
- Limitation of Low-cost, Mass fabrication of microneedle with arbitrary shapes, various dimensions



J.D. Kim et al., J. Controlled Release (2013)





 Recently, only few works about ISF extraction sensor applications
 C. G. Li et al.




BNS MEDICALS

Conventional MN fabrication technology

BNS

MEDICALS




We Can improve



•

Larger area of uniform microneedles with faster process time



Patents by Raphas. Co., Ltd. (collaboration with UTokyo, BJ Kim one of inventors)


- WO2017/200213 "METHOD FOR MANUFACTURING MICRONEEDLE" (PCT/KR2017/004058)
- ・ (韓国)特許10-2016-0061903号 出願日2016年5月20日, 2017年12月29日登録) 発明名称:マイクロニードル製造方法
- ・ (韓国)特許10-2016-0061909号 出願日2016年5月20日, 2017年9月14日登録) 発明名称:マイクロニードル製造用粘性物質供給装置

BNS MEDICALS

New fabrication methods by Kim Lab.

特許PCT/JP2018/035899

- Use the 3D printing to easily get the batch fabrication of MN array
- Make the dimension of the 3D printed needle shrink to micro-scale
- Active Pharmaceutical Ingredient (API) with MN for drug delivery




Microsystems & Nanoengineering 7:58 (2021)

BNS MEDICALS

• Objective

Deliver active pharmaceutical ingredients (APIs) into skin in a non-invasive & effective way >> Innovate & Substitute conventional drug delivery using MNP technology

- Keywords: vaccine, sustained drug release, dissolvable MN, droplet-embedded MN
- Current targets: COVID-19 & other vaccines, antibiotics, sclerosis



COVID-19 Vaccine delivery MNP using vaccinia virus vector

MNP with HA microdroplets embedded^[2]


[1] The 13th Symposium on Micro-Nano Science and Technology, 15P2-PN-5 (2022), [2] JSPE Spring Meeting, G103 (2021)


Light (Optical) Therapy MNP (poke, and irridiate) Optical group 18

• Objective

Develop MN array to treat skin-related diseases directly >> <u>Realize fast, simple, and low-</u> <u>cost treatment / Establish novel light therapy (Photodynamic Therapy, PDT) using MNP</u>

- Keywords: light/optical therapy, photodynamic therapy (PDT), skin diseases
- Current targets: melanoma, acne, telangiectasia, hair removal, and so on





Optical MNP to treat telangiectasia^[2]


[1] Biomedical Optics Express, Vol.13, Issue 2 (2022), [2] JSPE Spring Meeting, G0101 (2021)





Porous Microneedles@B.J. Kim Lab.

Sensor – sampling by "Porous Needles"




Scientific Reports, 12, 10693 (2022). https://doi.org/10.1038/s41598-022-14725-6

Sensor group 20

• Objective

Develop MNP to extract interstitial fluid (ISF) & analyze ISF for sensing & monitoring the change of body functions >> Realize fast & simple diagnosis on site as healthcare device

- Keywords: porous MN, capillary action, interstitial fluid (ISF), colorimetric sensing
- Current targets: glucose, antibodies, cholesterol, cortisol, hormones, and so on





[1] Medical Devices and Sensors, Vol.3, Issue 4, e10109 (2020), [2] Scientific Reports, Vol.12, 10693 (2022), [3] JSPE Autumn Meeting, G31 (2021)

Biosensor MNP (Porous MN details)

Sensor group 21

Microparticle preparation using microfluidic technology





Prevention, Remote medicine, Digital healthcare

Our Mission

We believe that prevention is better than cure.
Preventive solutions should be widely accessible, convenient, and accurate.

- Preventive medicine
- Regenerative medicine

Successful Aging







Measuring "People"

BNS MEDICALS



Hierarchy of accuracy

Wearable sensors

Motion-Tracking sensors

- Accelerometer, Gyro, Magnetometer
- GNSS(GPS, Galileo, Beidou, GLONASS)


Bodily Function sensors

- Heart rate, Pulse Oximetry
- Temperature

BNS


MEDICALS

Chemical/electrical: RF communication





@MC10 BioStamp





Bio markers -> Fluidic Biomarkers for smart bandages

	Measurement	Input Needed	Connection	Continuous
Temperature	Electrical	Voltage	Skin Contact Electrodes	Yes
Electrocradiogram	Electrical	Passive	Adhesive Electrodes	Yes
Photoplethysmograph	Optical	Light	Adhesive Sensor	Yes
Electrolytes	Potentiometry	Wicked Sweat/Blood	Wick	Yes
Blood Gasses	Amperometry	Capillary Blood	Microneedle	Yes
DNA Markers	DNA	Nucleic Acid Amplification/Fluid Sample	Swab/Tissue Sample	No
Protien Markers	Eletrochemical/Optical	Swabbed Blood/Sweat/Urine/Sweat	Swab	Maybe

Biomarkers examples


- Neuropeptides (NpY, Orexin A..), Catecholamines
- Cytokines, Corticosteroids
- PSMA/Antigens
- Glucono Lactone (glucose oxidase)
- Saccharide (boronic acid)





Our Solution


We make self-monitoring sensors for everyone.



BNS MEDICALS



健康・疾患評価に用いられているマーカーとその分類




Glucose sensor


to extract the interstitial fluid

(ISF)

既に動物実験に



BNS MEDICALS



1 in 11

Diabetes Mellitus



It is estimated that 415 million people are living with diabetes in the world

Diabetes is a leading cause of death and disability worldwide.



BNS MEDICALS



GROWING DANGER

Type 2 diabetes increasing in every country every year. 78,000 children develop type 1 diabetes every year

GOVERNMENT NEEDS

Diabetes caused at least 465 billion USD in healthcare expenditures in 2011. (11% total healthcare expenditures in adults)

More Problems

LIMITED DIAGNOSTIC SOLUTIONS


Current devices are expensive and obtrusive for pre-diabetes and diabetes patients. The blood collecting process is painful, requires administration, and nobody has the time for it these days.

80% ARE NOT AWARE

Approximately 88 million American adults—more than 1 in 3—have pre-diabetes. Of those with pre-diabetes, more than 80% don't know they have it.

80% CAN'T AFFORD

Nearly 80% of people with diabetes live in low and middle-income countries. Current mass glucose monitoring solutions are expensive for governments .




Why Now?

ACT BEFORE IT'S TOO LATE


Worldwide diabetes can be treated and its consequences avoided or delayed with diet, physical activity, and medical treatments but most importantly: <u>Regular Diagnostics</u>.

BNS

key tech: Biodegradable, interconnected Porous Microneedles for Sensing Innovation- Bio sensor patch: Micro Lateral Flow chip to interface porous MNs




Application of device






Results of fabrication




Research object 1 : porous MN Research object 2 : PLGA biodegradable polymer

BNS MEDICALS




Comparisons with previous study on glucose monitoring



BNS (Bio molecular Needling System) Medicals @ BJ . Kim Lab., IIS, The University of Tokyo

BNS MEDICALS

Comparison of with previously developed glucose sensor



- The fabricated and applied sensor in this work has a satisfying LoD compared to previous research
- The device proposed in this work has as an advantage in usability compare to other sensor


BNS MEDICALS


Continous Glucose sensor patch: Microfluidic chip to interface porous MNs

Requirements

BNS MEDICALS


- Flat surface to support the porous MNs
- Inlet ports to extract the interstitial fluid (ISF)
- Microchannels to transport the fluid






Porous Needle -> 3D Micro Fractal Pipettes for liquid sample handling

Capillary force






Review of Scientific Instruments, 91, 086104, 2020 https://doi.org/10.1063/5.0018456



Porous Microneedles




Diagnosing COVID-19

Tool for Painless, Rapid Detection

Scientific Reports, 10.1038/s41598-022-14725-6, 2022



2. マイクロニードルパッチの展開: 新型コロナウイルス抗体検査パッチ



■ 従来の検査デバイスをパッチ内に実装(動物実験成功)
 ■ 測定原理は免疫学的検定→将来の感染症にも有効





2021.3.23 TV 朝日 2021.3.24 TBS



東大、新型コロナウイルス感染症の無痛・迅速診断パッチを 開発

記事利用について

2022/7/1 18:01 日本経済新聞 電子版

発表日:2022年07月01日

日本經濟新聞

新型コロナウイルス感染症の無痛・迅速診断パッチの開発

――マイクロニードルを用いた、貼るだけの抗体検出へ――

1.発表者:

金 範● (◇) (東京大学 生産技術研究所 教授)

鮑 蕾蕾(東京大学 大学院工学系研究科 精密工学専攻 博士課程3年)

◇教授名の正式表記は添付の関連資料を参照

2. 発表のポイント:

◆皮膚内の体液から、新型コロナウイルスに対する抗体(lgMおよびlgG)を検出しうることを初めて示した。また、皮膚内で分解する多孔質マイクロニードルの作製方法を新たに開発した。

◆開発した多孔質マイクロニードルと抗原抗体反応を組み合わせ、既存の検出キットと同 等以上の感度を示す、これまでにないパッチ型の抗体検出デバイスを開発した。

◆パッチ型抗体検出デバイスは小型かつ低侵襲(無痛)で、皮膚に貼るだけで使用でき、 将来的にはさまざまな感染症の迅速なスクリーニングへの応用が期待される。

3. 発表概要:

東京大学 生産技術研究所の金 範● 教授、大学院工学系研究科 精密工学専攻 博士課程3年 の鮑 蕾蕾 大学院生らの研究グループは、従来の注射針を用いた採血に代えて、皮膚に貼る だけで抗体検出ができる、多孔質マイクロニードル(注1)とイムノクロマトアッセイ(注 2)を組み合わせた新しいパッチ型抗体検出デバイス(図1、Porous MicroNeedle and

https://www.iis.u-tokyo.ac.jp/ja/news/3908/

scientific reports

Check for updates

www.nature.com/scientificreports

OPEN Anti-SARS-CoV-2 IgM/IgG antibodies detection using a patch sensor containing porous microneedles and a paper-based immunoassay

Leilei Bao, Jongho Park, Boyu Qin & Beomjoon Kim

Infectious diseases are among the leading causes of mortality worldwide. A new coronavirus named severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) was identified in Wuhan, China in 2019, and the World Health Organization (WHO) declared its outbreak, coronavirus disease 2019 (COVID-19), as a global pandemic in 2020, COVID-19 can spread quickly from person to person. One of the most challenging issues is to identify the infected individuals and prevent potential spread of SARS-CoV-2. Recently, anti-SARS-CoV-2 immunoglobulin M (IgM) and immunoglobulin G (IgG) antibody tests using immunochromatographic methods have been used as a complement to current detection methods and have provided information of the approximate course of COVID-19 infection However, blood sampling causes pain and poses risks of infection at the needle puncture site. In this study, a novel patch sensor integrating porous microneedles and an immunochromatographic assay (PMNIA) was developed for the rapid detection of anti-SARS-CoV-2 lgM/lgG in dermal interstitial fluid (ISF), which is a rich source of protein biomarkers, such as antibodies. Biodegradable porous microneedles (MNs) made of polylactic acid were fabricated to extract ISF from human skin by capillary effect. The extracted ISF was vertically transported and flowed into the affixed immu biosensor, where specific antibodies could be detected colorimetrically on-site. Anti-SARS-CoV-2 IgM/ IgG antibodies were simultaneously detected within 3 min in vitro. Moreover, the limit of detection of anti-SARS-CoV-2 IgM and IgG concentrations was as low as 3 and 7 ng/mL, respectively. The developed device integrating porous MNs and immunochromatographic biosensors is expected to enable minimally invasive, simple, and rapid anti-SARS-CoV-2 IgM/IgG antibody testing. Furthermore the compact size of the MN and biosensor-integrated device is advantageous for its widespread use. The proposed device has great potential for rapid screening of various infectious diseases in addition to COVID-19 as an effective complementary method with other diagnostic tests.

At the end of 2019, a novel coronarirus, severe acute respiratory syndrome coronarirus (SARE-CO-2), was identified, which causes coronarirus disease 2019 (COVID-19). It spread worldwide within 3 months owing to its high infectivity⁵². In March 2020, the World Health Organization (WHO) announced the COVID-19 outbreak as a global pandemic? A COVID-19 infection spreads quickly from person to person and its symptoms include fatigue, cough, fever, dyspnea, ansonia, and ageusia; more severe symptoms include respiratory insufficiency, which can be life-threatening⁶². Furthermore, the rate of asymptomatic infections is proported as 16–38%, which brings difficulties in identifying all the individuals with SARE-CoV-2 infectiod. COVID-19 vaccines are effective in reducing infection risk and virus transmission; however, the proportion of the population fully vaccinated against COVID-19 remains less than 10% in several low-income countries⁸². Therefore, one of the current global challenges is to identify both symptomatic and asymptomatic patients as soon as prevent potential spread of SARS-CoV-2.

Currently, real-time reverse transcription polymerase chain reaction (RT-PCR) is the predominant detection method and remains the gold standard for COVID-19 diagnosis⁹. However, there are certain drawbacks


Institute of Industrial Science, The Univeristy of Tokyo, 4-6-1 Komaba, Meguro-ku, Tokyo 153-8505, Japan. ⁵⁶email: bjoonkim@iis.u-tokyo.ac.jp


Scientific Reports | (2022) 12:10693 | https://doi.org/10.1038/s41598-022-14725-6

Nature "Scientific Reports", 10.1038/s41598-022-14725-6, 2022

natureportfolio

SARS-CoV-2 & Diagnosis






A New coronavirus was identified in Dec, 2019: Severe acute respiratory syndrome corona virus 2 (SARS-CoV-2)


- High Transmission rate
- Severe symptoms
- High asymptomatic rate

Global challenge **Diagnose & guarantine** positive viral carriers

Current COVID-19 diagnostics





- Real-time reverse transcription polymerase chain reaction
- SARS-CoV-2 antigen lateral-flow immunoassay (LFIA) test



[Safiabadi Tali, S. H., 2021]

45






[Dhamad, A. E., 2020]


Porous MNs for SARS-CoV-2 diagnosis

46

- Developed a portable and self-applied device for minimally-invasive & rapid detection of anti-SARS-CoV-2 IgM and IgG in dermal ISF.
- Integrated immunochromatographic assay for target Abs detection using porous MNs for painless ISF extraction.




Antibody detection via interstitial fluid (ISF)




PLA Porous MNs

Fabrication using single emulsion method





Schematic diagram of fabrication process


Evaluation results of PLA porous MNs



Dimensions of porous PLA MNs after heat treatment








Porous Microneedles & immuNochromatographIc Assay


Working principle of lateral-flow PMNIA




Evaluation of lateral-flow PMNIA

Anti-SARS-CoV-2 IgM & IgG detection

(a) IgM positive



(b) IgG positive



(c) IgM & IgG positive




(d) Negative




* Scale bar: 5 mm





a. 5 µg/mL anti-SARS-CoV-2 IgM antibody; **b**. 5 µg/mL anti-SARS-CoV-2 IgG antibody;


Comparison with previous researches (LoD)



Comparable or higher sensitivity than currently available commercial kit

>> Demonstrated that the proposed lateral-flow PMNIA can be a promising device for painless detection of SARS-CoV-2-specific antibody in ISF

Comparison of complexity of diagnostics




- Assessment and characteristics of proposed lateral-flow and vertical-flow PMNIAs
- Antibody detection results of proposed PMNIAs can be observed by naked-eyes rapidly
- LoD for anti-SARS-CoV-2 IgM and IgG was measured and lateral-flow PMNIA revealed high sensitivity compared with commercial LFIA kits



The proposed lateral-flow PMNIA is a prospective diagnostic tool to painlessly detect SARS-CoV-2-specific antibody in ISF and obtain information regarding the infection stage

Thank you for your attention!



Please, click here!



Appreciate Dr. Anthony W. Coleman@ Lyon Prof. Maruoka @国立国際医療センター Supported by SEIKEN Special TENKAIKENKYU JSPS科研費、国立国際医療センター、東大病院、 AmtixBio(株)、SUNROI(株), Lintec(株), Premier Wellness Science(株), CG bio社, etc…